Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor

KM. Lemberg, ES. Ali, M. Krecmerova, JMH. Aguilar, J. Alt, DE. Peters, L. Zhao, Y. Wu, N. Nuha, JM. Asara, V. Staedtke, CA. Pratilas, P. Majer, R. Rais, I. Ben-Sahra, BS. Slusher

. 2023 ; 22 (12) : 1390-1403. [pub] 2023Dec01

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000514

Grantová podpora
R01 CA229451 NCI NIH HHS - United States
T32 OD011089 NIH HHS - United States
R01 GM135587 NIGMS NIH HHS - United States
T32 OD011089 ODCDC CDC HHS - United States
R01 NS103927 NINDS NIH HHS - United States
R01 GM143334 NIGMS NIH HHS - United States

Malignant peripheral nerve sheath tumors (MPNST) are highly aggressive soft-tissue sarcomas that arise from neural tissues and carry a poor prognosis. Previously, we found that the glutamine amidotransferase inhibitor JHU395 partially impeded tumor growth in preclinical models of MPNST. JHU395 inhibits de novo purine synthesis in human MPNST cells and murine tumors with partial decreases in purine monophosphates. On the basis of prior studies showing enhanced efficacy when glutamine amidotransferase inhibition was combined with the antimetabolite 6-mercaptopurine (6-MP), we hypothesized that such a combination would be efficacious in MPNST. Given the known toxicity associated with 6-MP, we set out to develop a more efficient and well-tolerated drug that targets the purine salvage pathway. Here, we report the discovery of Pro-905, a phosphoramidate protide that delivered the active nucleotide antimetabolite thioguanosine monophosphate (TGMP) to tumors over 2.5 times better than equimolar 6-MP. Pro-905 effectively prevented the incorporation of purine salvage substrates into nucleic acids and inhibited colony formation of human MPNST cells in a dose-dependent manner. In addition, Pro-905 inhibited MPNST growth and was well-tolerated in both human patient-derived xenograft (PDX) and murine flank MPNST models. When combined with JHU395, Pro-905 enhanced the colony formation inhibitory potency of JHU395 in human MPNST cells and augmented the antitumor efficacy of JHU395 in mice. In summary, the dual inhibition of the de novo and purine salvage pathways in preclinical models may safely be used to enhance therapeutic efficacy against MPNST.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000514
003      
CZ-PrNML
005      
20240213093227.0
007      
ta
008      
240109s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1535-7163.MCT-23-0258 $2 doi
035    __
$a (PubMed)37616542
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Lemberg, Kathryn M $u Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland $u Johns Hopkins Drug Discovery, Baltimore, Maryland $1 https://orcid.org/0000000315119322
245    10
$a Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor / $c KM. Lemberg, ES. Ali, M. Krecmerova, JMH. Aguilar, J. Alt, DE. Peters, L. Zhao, Y. Wu, N. Nuha, JM. Asara, V. Staedtke, CA. Pratilas, P. Majer, R. Rais, I. Ben-Sahra, BS. Slusher
520    9_
$a Malignant peripheral nerve sheath tumors (MPNST) are highly aggressive soft-tissue sarcomas that arise from neural tissues and carry a poor prognosis. Previously, we found that the glutamine amidotransferase inhibitor JHU395 partially impeded tumor growth in preclinical models of MPNST. JHU395 inhibits de novo purine synthesis in human MPNST cells and murine tumors with partial decreases in purine monophosphates. On the basis of prior studies showing enhanced efficacy when glutamine amidotransferase inhibition was combined with the antimetabolite 6-mercaptopurine (6-MP), we hypothesized that such a combination would be efficacious in MPNST. Given the known toxicity associated with 6-MP, we set out to develop a more efficient and well-tolerated drug that targets the purine salvage pathway. Here, we report the discovery of Pro-905, a phosphoramidate protide that delivered the active nucleotide antimetabolite thioguanosine monophosphate (TGMP) to tumors over 2.5 times better than equimolar 6-MP. Pro-905 effectively prevented the incorporation of purine salvage substrates into nucleic acids and inhibited colony formation of human MPNST cells in a dose-dependent manner. In addition, Pro-905 inhibited MPNST growth and was well-tolerated in both human patient-derived xenograft (PDX) and murine flank MPNST models. When combined with JHU395, Pro-905 enhanced the colony formation inhibitory potency of JHU395 in human MPNST cells and augmented the antitumor efficacy of JHU395 in mice. In summary, the dual inhibition of the de novo and purine salvage pathways in preclinical models may safely be used to enhance therapeutic efficacy against MPNST.
650    _2
$a lidé $7 D006801
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    12
$a neurofibrosarkom $7 D018319
650    _2
$a glutamin $7 D005973
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a antimetabolity $x terapeutické užití $7 D000963
650    12
$a nádory nervové pochvy $x farmakoterapie $7 D018317
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ali, Eunus S $u Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois $1 https://orcid.org/0000000294773500
700    1_
$a Krecmerova, Marcela $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000177801795
700    1_
$a Aguilar, Joanna Marie H $u Johns Hopkins Drug Discovery, Baltimore, Maryland $1 https://orcid.org/0000000204991927
700    1_
$a Alt, Jesse $u Johns Hopkins Drug Discovery, Baltimore, Maryland $1 https://orcid.org/0000000154407891
700    1_
$a Peters, Diane E $u Johns Hopkins Drug Discovery, Baltimore, Maryland $u Department of Pharmacology and Molecular Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland $1 https://orcid.org/0000000341856203
700    1_
$a Zhao, Liang $u Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland $1 https://orcid.org/0000000221266778
700    1_
$a Wu, Ying $u Johns Hopkins Drug Discovery, Baltimore, Maryland $1 https://orcid.org/0000000262884636
700    1_
$a Nuha, Naziba $u Johns Hopkins Drug Discovery, Baltimore, Maryland $1 https://orcid.org/0009000431589679
700    1_
$a Asara, John M $u Division of Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard University School of Medicine, Boston, Massachusetts $1 https://orcid.org/0000000174502589
700    1_
$a Staedtke, Verena $u Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland $1 https://orcid.org/0000000278745585
700    1_
$a Pratilas, Christine A $u Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland $1 https://orcid.org/0000000271160605
700    1_
$a Majer, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000218046934
700    1_
$a Rais, Rana $u Johns Hopkins Drug Discovery, Baltimore, Maryland $u Department of Pharmacology and Molecular Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland $u Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland $1 https://orcid.org/0000000340592453
700    1_
$a Ben-Sahra, Issam $u Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois $1 https://orcid.org/0000000193334162
700    1_
$a Slusher, Barbara S $u Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland $u Johns Hopkins Drug Discovery, Baltimore, Maryland $u Department of Pharmacology and Molecular Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland $u Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland $u Departments of Medicine, Neuroscience, Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland $1 https://orcid.org/0000000198144157
773    0_
$w MED00006616 $t Molecular cancer therapeutics $x 1538-8514 $g Roč. 22, č. 12 (2023), s. 1390-1403
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37616542 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093224 $b ABA008
999    __
$a ok $b bmc $g 2049271 $s 1210208
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 22 $c 12 $d 1390-1403 $e 2023Dec01 $i 1538-8514 $m Molecular cancer therapeutics $n Mol Cancer Ther $x MED00006616
GRA    __
$a R01 CA229451 $p NCI NIH HHS $2 United States
GRA    __
$a T32 OD011089 $p NIH HHS $2 United States
GRA    __
$a R01 GM135587 $p NIGMS NIH HHS $2 United States
GRA    __
$a T32 OD011089 $p ODCDC CDC HHS $2 United States
GRA    __
$a R01 NS103927 $p NINDS NIH HHS $2 United States
GRA    __
$a R01 GM143334 $p NIGMS NIH HHS $2 United States
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace